Tumor hypoxia has been recognized as a hindrance to successful radiation therapy for over 50 years. The search for small molecules to act as oxygen mimetics and selectively sensitize hypoxic tumors to radiotherapy has had many worthy candidates in the past, but none have been successful in Phase III clinical trials. In addition, attempts to overcome hypoxia by delivering more oxygen to the tumor, however, have been clinically disappointing, largely due to the functional limitations of the tumor vasculature. Increasing systemic oxygen delivery does not result in increased tumor oxygenation. Instead of reducing hypoxia by increased delivery of oxygen, this application proposes to limit hypoxia by reducing oxygen consumption within the tumor. If the supply of oxygen delivered to the tumor is constant, then transient reduction in demand will result in increased tumor oxygenation. We have identified several commonly prescribed drugs (papaverine is the lead compound) that dramatically reduce mitochondrial function in vitro. We propose to test the hvpothesis that pharmacologic down regulation of mitochondrial metabolism will reduce cellular demand for oxygen and result in decreased tumor hypoxia and radiosensitization of model tumors. This approach will be especially effective when added to hypofractionated radiation protocols where oxygen enhancement can result in a profound increase on overall tumor cell killing. We have organized this proposal into the following four specific aims. 1) Determine the effective concentration of two mechanistically different, FDA approved drugs to inhibit the mitochondrial function of a panel of cancer cell lines in vitro. 2) Quantify the biochemical effect of drug treatment on mitochondrial function, tumor hypoxia, and glucose consumption in model tumors with Core B. 3) Establish the optimal level of radiosensitization in both subcutaneous and orthotopic model tumors treated with metabolic modifiers in collaboration with Project 1 and 4, and 4) Initiate a clinical trial that directly measures tumor oxygenation changes in patients with advanced Head and Neck Squamous Cell Carcinomas (HNSCC) with Project 2. It is important to note that because normal tissue is typically well oxygenated, systemic delivery of well tolerated metabolic modifiers will specifically radiosensitize tumors, without causing enhanced normal tissue toxicity.

Public Health Relevance

Almost half of all human cancers receive some type of radiotherapy as part of their treatment. However, tumors vary considerably in their sensitivity to radiation, due in part the amount of oxygen present We propose to make tumors more radiation sensitive by increasing oxygen levels within the tumor. We will repurpose FDA approved drugs for this novel application. We will test model tumors in mice for increased radiation sensitivity, and patient tumors for increased oxygenation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA067166-16A1
Application #
8528127
Study Section
Special Emphasis Panel (ZCA1-RPRB-2 (J1))
Project Start
1997-04-01
Project End
2018-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
16
Fiscal Year
2013
Total Cost
$202,017
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Bobko, Andrey A; Evans, Jason; Denko, Nicholas C et al. (2016) Concurrent Longitudinal EPR Monitoring of Tissue Oxygenation, Acidosis, and Reducing Capacity in Mouse Xenograft Tumor Models. Cell Biochem Biophys :
Zeidan, Youssef H; Xiao, Nan; Cao, Hongbin et al. (2016) Botulinum Toxin Confers Radioprotection in Murine Salivary Glands. Int J Radiat Oncol Biol Phys 94:1190-7
Jiang, Dadi; Lynch, Connor; Medeiros, Bruno C et al. (2016) Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein Response. Sci Rep 6:33353
Vilalta, Marta; Rafat, Marjan; Graves, Edward E (2016) Effects of radiation on metastasis and tumor cell migration. Cell Mol Life Sci 73:2999-3007
Rankin, Erinn B; Giaccia, Amato J (2016) Hypoxic control of metastasis. Science 352:175-80
Sun, Ramon C; Koong, Albert; Giaccia, Amato et al. (2016) Measuring the Impact of Microenvironmental Conditions on Mitochondrial Dehydrogenase Activity in Cultured Cells. Adv Exp Med Biol 899:113-20
Leszczynska, Katarzyna B; Göttgens, Eva-Leonne; Biasoli, Deborah et al. (2016) Mechanisms and consequences of ATMIN repression in hypoxic conditions: roles for p53 and HIF-1. Sci Rep 6:21698
Olcina, Monica M; Giaccia, Amato J (2016) Reducing radiation-induced gastrointestinal toxicity - the role of the PHD/HIF axis. J Clin Invest 126:3708-3715
Alagappan, Muthuraman; Jiang, Dadi; Denko, Nicholas et al. (2016) A Multimodal Data Analysis Approach for Targeted Drug Discovery Involving Topological Data Analysis (TDA). Adv Exp Med Biol 899:253-68
LaGory, Edward L; Giaccia, Amato J (2016) The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol 18:356-65

Showing the most recent 10 out of 177 publications